- Company
- Hepatitis B drug market remakes ₩300B after 6 years
- by Kim, Jin-Gu Feb 4, 2025 05:55am
- The outpatient prescription market for hepatitis B drugs expanded again last year to exceed KRW 300 billion. This is the first time the market has exceeded the mark in 6 years since 2018. Gilead Sciences’ Vemlidy drove the market growth with a 15% increase in sales from KRW 61.9 billion to KRW 71.3 billion in 1 year, while the combined pres
- Company
- 'Tibsovo' reapplies for bile duct cancer indication reimb
- by Eo, Yun-Ho Feb 4, 2025 05:55am
- 'Tibsovo,' which is indicated for the treatment of bile duct cancer (cholangiocarcinoma) and acute myeloid leukemia (AML), reapplies for obtaining insurance reimbursement. According to industry sources, Servier Korea has submitted a reimbursement application for cholangiocarcinoma indication of Tibsovo (ivosidenib), a drug targeting the i
- Company
- Lixiana leads the DOAC market..generics make advances
- by Kim, Jin-Gu Feb 4, 2025 05:55am
- Daiichi Sankyo's Lixiana (edoxaban) is further solidifying its dominance in the direct-acting oral anticoagulant (DOAC) market. Prescriptions grew 12% year-on-year, and its share of the total market expanded to 45%. Sales of Eliquis (apixaban) and Xarelto (rivaroxaban), on the other hand, have faltered. Eliquis saw its first year-over-
- Company
- ROS1 targeted cancer drug 'Augtyro' nearing mkt entry
- by Eo, Yun-Ho Feb 3, 2025 05:52am
- The ROS1-targeting anticancer drug, 'Augtyro,' is expected to be commercialized in South Korea. According to industry sources, Bristol Myers Squibb (BMS) Korea is close to receiving approval from the Ministry of Food and Drug Safety (MFDS) for Augtyro (repotrectinib), an anticancer drug that can be used regardless of cancer types. This
- Company
- Samsung Bioepis loses Eylea appeal trial in the US
- by Cha, Jihyun Feb 3, 2025 05:52am
- The U.S. market entry of 'Eylea' biosimilar, a treatment for eye diseases, from Samsung Bioepis is stalled. The company recently lost a trial of appeal in addition to the previous motion filed by the developer for a preliminary injunction over a sales ban on an item. According to the biotechnology industry sources on January 31, the United S
- Company
- Jardiance is reimbursed for HFpEF
- by Whang, byung-woo Feb 3, 2025 05:52am
- The SGLT2 inhibitor Jardiance (empagliflozin) has been granted reimbursement across the full spectrum of heart failure in Korea, increasing its influence in the market. Boehringer Ingelheim Korea announced on the 31st that its drug will be granted reimbursement as of February 1st, under the Ministry of Health and Welfare notifications, fo
- Company
- ALS drug Qalsody to be commercialized in Korea
- by Eo, Yun-Ho Jan 31, 2025 05:56am
- Commercialization of the new drug ‘Qalsody’ for amyotrophic lateral sclerosis is expected in Korea. According to industry sources, Qalsody (tofersen), Biogen’s drug indicated for the treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation in the Superoxide Dismutase 1 (OD1) gene mutation, is undergoing a review for
- Company
- Epkinly may be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Jan 31, 2025 05:56am
- Epkinly, an innovative bispecific antibody drug that binds to T cells, may now be prescribed in general hospitals in Korea. According to industry sources, AbbVie Korea’s Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphoma (DLBCL) treatment Epkinly (epcoritamab) has recently passed the drug committee (DC) review of Asan Medi
- Company
- 'Latuda,' the new schizophrenia drug, can be prescribed
- by Eo, Yun-Ho Jan 31, 2025 05:56am
- 'Latuda,' a treatment for schizophrenia, becomes available for prescription at general hospitals. According to industry sources, Bukwang Pharmaceutical's Latuda (lurasidone) has passed the drug committees of tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospital, and Severance Hospital in Sinchon
- Company
- KDA ‘Concern on use of SGLT2 inhibitors for weight loss'
- by Whang, byung-woo Jan 31, 2025 05:56am
- As interest in weight loss has increased with the advent of new GLP-1 analogs, experts have warned of the risk of overuse of SGLT2 inhibitors for weight loss or cosmetic purposes. The Korean Diabetes Association has recently issued a series of statements on the safe use of SGLT2 inhibitors for both experts and the general public. As the nu
